April 15, 2026
2 min watch
COPENHAGEN, Denmark — In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses the Beamion LUNG-1 trial evaluating zongertinib in HER2-mutant advanced non-small cell lung cancer.
The phase 1b trial included treatment-naive patients with HER2 tyrosine kinase domain mutations who received 120 mg zongertinib (Hernexeos, Boehringer Ingelheim) as first-line therapy once daily.
“This had a really exciting response rate of 77%, disease control rate of 96%, with only 1% of patients with primary progression, which is super exciting,” said Cooper, noting these results have “potential to change our practice patterns.”
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Heymach J, et al. Abstract 6MO. Presented at: European Lung Cancer Congress; March 25-28, 2026; Copenhagen, Denmark.
Disclosures:
Cooper reports honoraria from CancerGRACE, IDEOlogy Health, Intellisphere, MedStar Health, MJH Life Sciences and PeerDirect; consulting roles with AbbVie, Amgen, Boehringer Ingelheim, Daiichi Sankyo/AstraZeneca, Gilead Sciences, Novartis and Regeneron; and prior institutional research funding from AbbVie, Amgen, Daiichi Sankyo, Merck, Monte Rosa Therapeutics and Roche.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply